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Abstract
Background: Roux-en-Y gastric bypass (RYGB) surgery is associated with weight loss, improved insulin sensitivity and
glucose homeostasis, and a reduction in co-morbidities such as diabetes and coronary heart disease. To generate further
insight into the numerous metabolic adaptations associated with RYGB surgery, we profiled serum metabolites before and
after gastric bypass surgery and integrated metabolite changes with clinical data.
Methodology and Principal Findings: Serum metabolites were detected by gas and liquid chromatography-coupled mass
spectrometry before, and 3 and 6 months after RYGB in morbidly obese female subjects (n=14; BMI=46.261.7). Subjects
showed decreases in weight-related parameters and improvements in insulin sensitivity post surgery. The abundance of
48% (83 of 172) of the measured metabolites changed significantly within the first 3 months post RYGB (p,0.05), including
sphingosines, unsaturated fatty acids, and branched chain amino acids. Dividing subjects into obese (n=9) and obese/
diabetic (n=5) groups identified 8 metabolites that differed consistently at all time points and whose serum levels changed
following RYGB: asparagine, lysophosphatidylcholine (C18:2), nervonic (C24:1) acid, p-Cresol sulfate, lactate, lycopene,
glucose, and mannose. Changes in the aforementioned metabolites were integrated with clinical data for body mass index
(BMI) and estimates for insulin resistance (HOMA-IR). Of these, nervonic acid was significantly and negatively correlated with
HOMA-IR (p=0.001, R=20.55).
Conclusions: Global metabolite profiling in morbidly obese subjects after RYGB has provided new information regarding
the considerable metabolic alterations associated with this surgical procedure. Integrating clinical measurements with
metabolomics data is capable of identifying markers that reflect the metabolic adaptations following RYGB.
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Introduction
Obesityis characterized by the accumulationof excessbodyfatto
an extent that health is adversely affected via the development of co-
morbidities. Due to a scarcity of validated and safe therapies, Roux-
en-Y gastric bypass (RYGB) has become an increasingly effective
treatment for severely obese patients [1,2]. Following this
procedure, patients experience a significant loss of weight; however,
an unexpected and major outcome with gastric bypass surgery was
that deaths related to coronary heart disease and diabetes were
reduced by more than 50% and 90%, respectively [3]. Furthermore
RYGB results in significant metabolic changes that lead to major
improvements in blood glucose and insulin levels, insulin sensitivity
and hormonal responses, as well as decreasing inflammatory
markers [4,5]. Lipid metabolism is also modified following the
procedure, as demonstrated by decreases in total cholesterol and
LDL-cholesterol, and increases in HDL-cholesterol [6]. Significant
changes in the secretion of gastric and intestinal peptides such as
glucagon-like peptide-1 (GLP-1), ghrelin, and peptide YY have also
beendemonstratedfollowing RYGB [7,8]. While a growingbody of
evidence supports the overall health benefits of bariatric surgery to
treat morbid obesity, such a procedure is also associated with risks
includingmortality(,1%)and several complications suchasvenous
thromboembolism, gallstone formation, and nutritional deficiencies
[9]. Taken together, this procedure has a significant impact on a
patient’s whole-body metabolism and is therefore a unique model to
understandthephysiologicalandmolecularmechanismsunderlying
the observed metabolic alterations.
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7905Unraveling the immediate and long-term adaptations associated
with gastric bypass surgery has proved challenging, predominantly
because the consequences of this procedure include caloric
restriction, diminished nutrient absorption, reduced adipose mass,
modified gut hormone signaling, and changes in whole-body
glucose metabolism that can each cause numerous physiological
and metabolic adaptations. Because of a growing interest to treat
type-II diabetes with gastric bypass surgery, the rapid and long-
term improvement of insulin sensitivity and the reduction of
diabetes in subjects post surgery has become a primary axis of
interest. Several hypotheses have been postulated to explain the
improved insulin sensitivity witnessed post surgery, and include the
altered secretion of gut hormones [10], modifications in intestinal
gluconeogenesis [11], and changes in intramyocellular lipid
content [12]. While the definitive explanation for improved
insulin sensitivity post RYGB remains unclear, it is most probably
a combination of the aforementioned hypotheses.
One informative approach that has not yet been used to study
the metabolic adaptations following RYGB is metabolite profiling,
despite the fact that this approach has successfully generated new
knowledge regarding the metabolic modifications associated with
obesity and diet-induced weight loss [13–16]. Our present work
has analyzed the metabolite profiles in the serum of morbidly
obese female subjects who underwent RYGB. Subjects were
further sub-divided into obese (OB) and obese/diabetics (OB/D)
to identify metabolites associated with surrogates of steady-state
insulin sensitivity. Our results provide new knowledge regarding
the global alterations in serum metabolite profiles post RYGB and
position nervonic acid as a possible marker of insulin sensitivity.
Materials and Methods
Ethics Statement
The Ethics Committees of the Ho ˆtel-Dieu Hospital approved
the clinical investigations and all subjects gave written consent.
Subjects
Fourteen obese women (11 Caucasian, 2 Caribbean from French
Antilles, and 1 African) involved in a gastric surgery program were
prospectively recruited from the Ile-de-France region between 2005
and 2006 in the Department of Nutrition, Center of Reference for
Medical and Surgical Care of Obesity, CREMO, Ho ˆtel-Dieu (Paris,
France). Patients met the criteria for obesity surgery, i.e.
BMI$40 kg/m
2 or $35 kg/m
2 with at least two co-morbidities
(hypertension, type-II diabetes, dyslipidemia or obstructive sleep
apnea syndrome). The preoperative evaluation included medical
history, physical, nutritional, metabolic, cardiopulmonary, and
psychological assessments. Subject weight was stable (i.e. variation
of less than 62 kg) for at least 3 months prior to operation. Subjects
did not demonstrate evidence of acute or chronic inflammatory
disease, infectious diseases, viral infection, cancer and/or known
alcohol consumption (.20 g per day). According to the criteria of
fasting glycemia over 7 mM or the use of an anti-diabetic drug, 5
subjects were also type 2 diabetics (4 Caucasians and 1 Caribbean
from French Antilles). These five subjects (referred to hereon as the
OB/D group) were treated with metformin and hypolipemic drugs
(either fibrates or statins). Two subjects were additionally treated
withinsulin.Thedurationofdiabetesinthese5subjectswas7.461.0
years(rangebetween5–11years).Inthenon-diabeticgroup(referred
to hereon as the OB group), none were treated with hypolipemic
drugs. Furthermore, an oral glucose tolerance test (OGTT) was
systematically performed before RYGB and confirmed that all
patients in the OB group had glucose levels less than 11 mmol/l
(200 mg/dl) inthe twohoursfollowing a 75 g oral glucosechallenge.
Clinical Assessment
All patients were assessed prior to Roux-en-Y surgery (i.e.
baseline or T0) and at 3 months and 6 months post surgery (T3
and T6). Blood samples were obtained at each time point and
stored at 220uC until used to assess lipid, insulin and glucose
values (enabling the determination of insulin sensitivity parame-
ters), leptin, and many other factors, outlined in [17]. Fat free body
mass and adiposity were determined by DXA (DEXA, GE Lunar
Prodigy Corporation, Madison, WI, USA) and resting energy
expenditure (REE) by indirect calorimetry after 12 hours fasting
(Deltatrac, Datex, France). The Homeostasis Model Assessment
(HOMA) was used to estimate steady state beta cell function
(HOMA%B) and insulin sensitivity (HOMA%S) [18]. HOMA
insulin resistance (IR) was determined using the HOMA
Calculator v2.2.2 (http://www.dtu.ox.ac.uk/). This index has
been validated in different populations (including normal-weight,
and obese type 2 diabetic and non-diabetic patients) in comparison
with the euglycemic-hyperinsulinemic clamp values [19]. As such,
the HOMA represents a useful index when studying morbidly
obese individuals in whom the evaluation of insulin sensitivity
using the clamp technique has understandable technical limita-
tions due to extreme BMI.
Dietary Assessment
Caloric intake and macronutrient proportions were evaluated
by a registered dietician in the hospital nutrition department.
Multivitamins and iron supplements were provided to avoid
deficiencies, which are a well-known secondary effect of this
bariatric surgery [20]. Blood measurements were performed
before and after the surgery to adjust the dose of oral supplements.
Serum iron, ferritin, the coefficient of saturation of iron in
transferrin, vitamins (A, D, E, B1, B12, B9), micronutrients
(selenium and zinc), and calcium were measured using routine bio-
clinical tests. All patients were in the normal ranges for all
aforementioned parameters at the different time points.
Metabolite Analysis
Three types of mass spectrometry analyses were applied to all
samples. GC-MS (gas chromatography-mass spectrometry; Agilent
6890 GC coupled to an Agilent 5973 MS-System, Agilent,
Waldbronn, Germany) and LC-MS/MS (liquid chromatography-
MS/MS; Agilent 1100 HPLC-System (Agilent, Waldbronn,
Germany) coupled to an Applied Biosystems API4000 MS/MS-
System (Applied Biosystems, Darmstadt, Germany)) were used for
broad profiling, as described in [21]. SPE-LC-MS/MS (solid
phase extraction-LC-MS/MS; Symbiosis Pharma (Spark, Emmen,
Netherlands) coupled to an Applied Biosystems API4000 MS/MS-
System (Applied Biosystems, Darmstadt, Germany)) was used for
the determination of catecholamine and steroid levels. In this
study, 242 metabolites fulfilled quality criteria for relative
quantification, and absolute quantification was performed for an
additional 14 metabolites. From a total of 256 metabolites, 172
were known metabolites, and 84 analytes were not chemically
identified with sufficient certainty (i.e. thus considered in the
present study to be unknown analytes). In this study, statistical
analysis and interpretation focused on known metabolites only. To
aid interpretation, metabolites were grouped into 11 biological
categories: amino acid and related; carbohydrates and related;
catecholamines and related; complex lipids and related; energy
metabolism and organic acids; fatty acids (free and from lipids);
purines, pyrimidines and related; steroids and related; vitamins,
cofactors and related; miscellaneous; and unknown metabolites.
Technical reference samples were measured in parallel with the
study samples in order to allow the relative quantification of
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samples were generated by randomly pooling serum from 15
healthy female controls (average age=48.962.1; BMI range of
21-24). A relative quantification for each metabolite was obtained
by normalizing peak intensity in the study samples to the median
peak intensity of the corresponding metabolite in the technical
reference samples measured in the same batch.
Metabolite Profiling by GC-MS and LC-MS/MS
Proteins were removed from serum samples (60 ul) by precipita-
tion. Subsequently polar and non-polar fractions were separated for
both GC-MS and LC-MS/MS analysis by adding water and a
mixture of ethanol and dichloromethane. For GC-MS analyses, the
non-polar fraction was treated with methanol under acidic
conditions to yield the fatty acid methyl esters derived from both
free fatty acids and hydrolyzed complex lipids. The polar and non-
polar fractions were further derivatized with O-methyl-hydroxya-
mine hydrochloride (20 mg/ml in pyridine, 50 ul) to convert oxo-
groups to O-methyloximes and subsequently with a silylating agent
(MSTFA, 50 ul) before GC-MS analysis [22]. For LC-MS/MS
analyses, both fractions were reconstituted in appropriate solvent
mixtures.Highperformance LC(HPLC)was performed bygradient
elution using methanol/water/formic acid on reversed phase
separation columns. Mass spectrometric detection technology was
applied as described in the patent US 7196323, which allows
targeted and high sensitivity ‘‘Multiple Reaction Monitoring’’
profiling in parallel to a full screen analysis. Use of the term
‘‘Minor’’ in figure and table legends indicatesthat quantification can
be affected by the co-occurrence of metabolites exhibiting identical
characteristics in the analytical methods. Literature data and/or
comparison with alternative methods (e.g. LC-MS/MS, GC-MS)
suggest that such metabolites are present at minor levels only.
Quantification by SPE-LC-MS/MS
Steroids and their related metabolites were measured by online
SPE-LC-MS/MS. Catecholamines and their related metabolites
were measured by online SPE-LC-MS/MS, as described by
Yamada et al [23]. Quantification was performed using stable
isotope-labeled standards.
ANOVA and Data Correction
An ANOVA model was developed to determine differences in
metabolite abundance over time (T0, T3, and T6) and between
groups (OB vs. OB/D). Metabolite data was log10-transformed
and a mixed-effects ANOVA was conducted for univariate data
analysis. Two modeling approaches were applied, where both
approaches began with fixed effects: sample_age (numeric, to
account for serum storage time), group (categorical: OB or OB/D)
and time (categorical: T0, T3, T6), and with random patient effect
(categorical, patient 1–14). The second more general approach
comprised an additional group:time interaction to account for
possible subgroup-specific changes over time (i.e. RYGB having
different effects on OB and OB/D subjects). The Akaike
information criterion (AIC) was applied for metabolite-specific
stepwise model evaluation and reduction of model complexity with
regards to fixed effects (all fixed effects except time were
considered optional). Experimental groups were compared and
statistically evaluated by t-statistics of model contrasts. The
estimated models were also used for data correction with regards
to sample_age by metabolite-specific subtraction of linear
sample_age estimations from log10-transformed data when
required (i.e. when sample_age was not removed by AIC model
complexity reduction). Analysis was conducted with statistical
software R version 2.4.1 (Copyright (C) 2006 ‘‘The R Foundation
for Statistical Computing’’, http://www.r-project.org/). In
FIGURE 1, unadjusted p-values are shown to indicate significance
levels. Furthermore, a ‘‘YES’’ is indicated in the corresponding
columns when changes remained significant (p,0.05) after
Bonferroni correction for multiple testing.
Multivariate Analysis of Metabolite Data
Partial least squares discriminant analysis (PLS-DA) of
sample_age-corrected data for the 172 known metabolites was
performed for classification analysis according to time (T0 vs. T3
vs. T6) and group (OB vs. OB/D, time-specific) using Umetrics
SIMCA-P software (Version 11.0, Umetrics AB, Umea, Sweden).
Model performance was quantified by Q2 values from leave-one-
subject-out cross validation.
Statistical Analysis of Clinical Data
The distribution of clinical data prior to surgery was tested using
the Shapiro-Wilk W Test. Non-parametric statistical tests were
used to assess clinical data over time (Mann-Whitney U-Test) and
between groups (Friedman test); performed using GraphPad Prism
version 4.0 software (GraphPad Software, Inc., California, USA).
All data is presented as mean6SEM.
Correlations between Metabolite and Clinical Data
Correlations between the abundance of 8 metabolites and two
clinical parameters (BMI or HOMA-IR) were assessed with a
Spearman correlation using JMP statistical software v5.1.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Clinical Characteristics of Subjects before and after RYGB
Our study population consisted of 9 obese (OB) subjects and 5
obese/diabetic (OB/D) female subjects, with an average BMI of
46.261.7. The OB/D subjects were all treated with metformin and
2 of these subjects were additionally treated with insulin. RYGB
resulted inthe expected and significant decreasesinbodymass index
(BMI), body weight (kg), fat mass (kg), and fat free mass (kg) from
T0 R T3 R T6 (TABLE 1). Resting energy expenditure (REE)was
decreased in all subjects following RYGB. Additionally, circulating
triglycerides and leptin levels were decreased post surgery. There
was a small, but significant, decrease in HDL-cholesterol between
T0 and T3; however, HDL-cholesterol levels recovered by T6; as
further supported by a lack of change in Apo-A1 levels between T0
and T6. Total caloric intake was significantly decreased following
RYGB; however, the relative proportion of protein, lipid and
carbohydrate consumed in the diet remained stable post surgery.
Since insulin injections prevent an accurate measure of endogenous
insulin and glucose levels, the 2 OB/D subjects treated with insulin
were removed prior to evaluating insulin resistance with the
HOMA. In the remaining 12 subjects, circulating glucose and
insulin levels decreased significantly post RYGB. A significant
decreaseininsulin resistance(evaluatedbyHOMA-IR)wasfound at
T3 and this decrease continued (albeit less dramatically) between T3
and T6 (FIGURE 2). Changes in HOMA-IR corresponded with
the expected increase in insulin sensitivity (HOMA%S) and a
decrease in beta-cell function (HOMA%B). These improvements
were observed in both OB and OB/D subgroups when considered
independently (data not shown).
Subjects in the OB/D group showed further improvements in
relation to their diabetic status. Prior to RYGB, HbA1c levels were
8.1%60.3 and at T3 the HbA1c levels dropped to 6.8%60.2
(p=0.06). Blood glucose levels in three of the five subjects
normalized after RYGB and anti-diabetic treatments were
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7905Figure 1. Various profiles for metabolites that change significantly at some point following RYGB. A profile is characterized by 3 dots,
which represent T0 (prior to RYGB), T3 and T6 (post surgery). An angled slope between two time points indicates a significant change (p,0.05) and a
flat slope between two time points indicates non-significant changes. Based on data derived from the mixed-effects ANOVA using all 14 subjects
together. (*1): Structure annotation is based on strong analytical evidence (combinations of chromatography, mass spectrometry, chemical reactions,
deuterium-labeling, database and literature search, as well as comparisons to similar/homologue/isomeric reference compounds). (*2): Metabolite
exhibits identical qualitative analytical characteristics (chromatography and mass spectrometry) compared to status (*1). Further structural and
analytical investigations of this metabolite - also in comparison to structurally identified or status (*1) metabolites - are still pending.
doi:10.1371/journal.pone.0007905.g001
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subjects treated with insulin prior to surgery showed improvements
post surgery (HbA1c levels dropped from 9.4% and 9.0% at T0 to
7.1% and 7.8% at T3); however insulin therapy was maintained
and diabetes was not resolved.
Global Metabolite Analysis
Partial least squares discriminant (PLS-DA) analysis of the 172
known metabolites measured in the serum of 14 subjects led to a
clear separation between the metabolite profiles before (T0), 3
months after (T3), and 6 months after (T6) gastric bypass surgery
(similarly observed with principal component analysis – data not
shown). The model, consisting of four components, had a
R2X(cumulative) of 0.430 and a Q2(cumulative) of 0.806 (selected
by leave-one-subject-out cross validation according to maximal
Q2(cum)). FIGURE 3 shows the first two out of four components
(for first two components, R2X(cum)=0.313, Q2(cum)=0.640).
Furthermore, there was a distinct separation between T0 and T3/
T6 (first PLS-DA component with large Q2_comp1=0.423) and a
further separation between the metabolite profiles at T3 and T6
with minor overlap in the second PLS-DA component. FIGURE 1
lists the 83 metabolites that changed significantly at some point
following RYGB in the 14 patients (mixed-effects ANOVA
without group:time-interaction). 89 known metabolites did not
change significantly following surgery. It is interesting to note that
Figure 2. Estimates for HOMA-IR before and after RYGB. HOMA-
IR was estimated for 12 subjects, 9 OB and 3 OB/D subjects. The OB/D
subjects were treated with metformin and not with insulin. A significant
reduction (T0 R T3, p=0.014; T0 R T6, p=0.001; T3 R T6, p=0.123) in
HOMA-IR occurred following RYGB, as assessed using a Friedman test.
Prior to RYGB, significant variability in HOMA-IR estimations was
observed between subjects (because OB and OB/D subjects are
combined); however, post RYGB, all subjects demonstrated a major
improvement in insulin sensitivity (illustrated by smaller error bars). Box
plots indicate no outlying data (i.e. above or below the whiskers), and
the band in the middle of the box indicates the median. ** p,0.01.
doi:10.1371/journal.pone.0007905.g002
Table 1. Clinical data in subjects at all 3 time points (T0, T3, and T6) examined.
Parameter T0 T3 T6
n=14 (all OB and OB/D subjects)
Age (yrs) 45.463.6
BMI (kg/m
2) 46.261.7 38.761.6
** 35.161.7
**
Weight (kg) 125.464.2 104.663.9
** 95.164.0
**
Fat mass (kg) 59.363.5 46.963.2
** 39.262.9
**
Free fat mass - FFM (kg) 60.261.5 54.161.7
** 51.961.8
**
Resting Energy Expenditure (kcal/d/kg FFM) 34.360.4 33.660.4
** 32.860.3
**
Total Cholesterol (mmol/l) 4.760.3 4.360.3 4.460.3
HDL-Cholesterol (mmol/l) 1.560.1 1.360.1
** 1.560.1
Triglycerides (mmol/l) 1.360.2 1.160.1
** 1.060.1
**
Apolipoprotein A-1 (g/l) 1.460.1 n/a 1.460.1
Leptin (ng/ml) 69.166.5 37.965.2
** 24.264.0
**
Total Caloric Intake (kcal/d) 18616149.2 9916101.6
** 1106698.4
**
% Protein 19.261.1 19.660.8 19.161.1
Nutrient Intake % Lipid 33.162.0 33.761.9 32.061.8
% Carbohydrate 47.662.2 46.761.9 47.562.8
n=12 (the two insulin treated OB/D subjects removed)
Glucose (mmol/l) 5.4460.34 4.9260.17
* 4.5360.10
**
Insulin (IU/l) 15.663.5 7.861.0
** 5.860.7
**
HOMA-IR 2.060.4 1.060.1
** 0.760.1
**
HOMA%S 70.3610.0 129.8629.7
** 207.8666.2
**
HOMA%B 134.5616.9 101.0612.1
** 92.567.6
**
All 14 subjects are included in the analysis of parameters related to body weight and lipids. Decreases after RYGB were observed for BMI, weight, fat mass, fat free mass,
resting energy expenditure and triglycerides. Leptin was also decreased significantly. While HDL-cholesterol decreased from T0 to T3, HDL-Cholesterol levels recovered
by T6 and are confirmed by the lack of change in Apo-A1 levels. Total caloric intake decreased after RYGB; however, the relative proportion of lipid, carbohydrate, and
protein consumed remained stable. When considering the 12 subjects not treated with insulin, glucose and insulin levels decreased post RYGB. Estimates for HOMA-IR
and HOMA%B decreased while HOMA%S increased after surgery. Data presented as mean6standard error. * represents p,0.1 and ** represents p,0.05, assessed by a
Friedman test.
doi:10.1371/journal.pone.0007905.t001
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changed significantly within the first 3 months post bypass surgery
and that 77% of these metabolites (59 of 77) did not subsequently
change between 3 and 6 months post surgery, despite the
continued significant decreases in BMI and body fat mass. Amino
acids and lipids were the two metabolite classes predominantly
altered following RYGB, where amino acids were decreased and
specific lipids were increased or decreased. Specifically, the
branched-chain amino acids (leucine, isoleucine, and valine)
decreased following RYGB. Further evidence for the regulation
of valine catabolism in particular was provided by the increased
serum abundance for b-aminoisobutyric acid, a product of valine
catabolism (FIGURE 1). With regards to lipid metabolites, we
observed increases in specific sphingosines, unsaturated fatty acids,
and phospholipids, while ceramide (d18:1, C24:0), triglycerides,
and saturated fatty acids decreased following RYGB.
Obese versus Obese/Diabetic Subjects
As previously mentioned, the population consisted of 9 OB and
5 OB/D subjects; therefore, we subsequently compared the
metabolite profiles of these two subgroups. PLS-DA displayed a
separation between OB and OB/D groups at each time point
before and after surgery (1 component PLS-DA model selected by
cross validation for T0 and T3, 2 component model for T6; T0 R
R2X=0.156 and Q2=0.528; T3 R R2X=0.146 and
Q2=0.529; and T6 R R2X=0.149 and Q2_comp1=0.585,
Q2(cum)=0.711). While many metabolites may contribute to this
separation, we considered only those metabolites that differed
between OB and OB/D subjects with p,0.05 at each time point
according to the mixed-effects ANOVA, allowing group:time-
interactions when statistically adequate. If the differences in
metabolite abundance between OB and OB/D groups did not
vary significantly with time (i.e. group:time interaction excluded by
AIC), the same p-value appears at all three time points. We
identified 33, 32, and 28 metabolites that differed significantly
(p,0.05) between OB and OB/D subjects at T0, T3, and T6,
respectively (TABLE 2). This is substantially more metabolites
than expected by chance, where one could expect 9 false-positives
per OB vs. OB/D comparison due to multiple testing at a 5%
significance level. The difference between the 33, 32 and 28
significant changes in the dataset and 9 expected false-positives
was found to be statistically significant (p=3
e-11 for T0, 1
e-10 for
Figure 3. Partial least squares discriminant analysis of 172 known metabolites in 14 subjects distinguishing the three classes: pre-
operative (T0) vs. 3 months after RYGB (T3) vs. 6 months after RYGB (T6). The first component distinctly classifies T0 vs. after RYGB
(Q2=0.423), the second component further distinguishes T3 and T6 (Q2(cum)=0.640 for two-component PLS-DA model). Model performance was
quantified by Q2 values from leave-one-subject-out cross validation. Q2 depicts the fraction of the total variation that is predicted by each PLS
component, while Q2(cum) depicts the cumulated fraction of the total variation predicted by the model.
doi:10.1371/journal.pone.0007905.g003
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Prior to surgery (T0) 3 months post surgery (T3) 6 months post surgery (T6)
Metabolite p-value Greater in Metabolite p-value Greater in Metabolite p-value Greater in
1,5-Anhydrosorbitol 0.00004 OB 1,5-Anhydrosorbitol 0.0002 OB Valine 0.0004 OB/D
Ascorbic acid 0.0020 OB/D Ascorbic acid 0.0020 OB/D Ascorbic acid 0.0020 OB/D
Testosterone 0.0024 OB 11-Deoxycortisol 0.0032 OB/D Leucine 0.0030 OB/D
Normetanephrine 0.0040 OB Hypoxanthine (minor: Inosine) 0.0041 OB/D 1,5-Anhydrosorbitol 0.0032 OB
Lycopene 0.0043 OB Lycopene 0.0043 OB myo-Inositol-2-phosphate
(minor: Fructose-6-phosphate,
Glucose-6-phosphate, myo-
Inositol-1-phosphate, myo-
Inositol-4-phosphate)
0.0033 OB/D
Asparagine 0.0046 OB/D Asparagine 0.0046 OB/D Lycopene 0.0043 OB
Lysophosphatidylcholine
(C18:2) (*2)
0.0059 OB Lysophosphatidylcholine
(C18:2) (*2)
0.0059 OB Asparagine 0.0046 OB/D
Androstenedione 0.0062 OB Phosphatidylcholine (C18:0,
C18:1) (*2)
0.0064 OB/D Lysophosphatidylcholine
(C18:2) (*2)
0.0059 OB
Linoleic acid (C18:cis[9,12]2) 0.0070 OB Cholic acid 0.0088 OB/D Proline 0.0061 OB/D
Phosphatidylcholine No 02 (*2) 0.0083 OB/D Cysteine (minor: Cystine) 0.0091 OB/D Xanthine 0.0082 OB/D
Cysteine (minor: Cystine) 0.0091 OB/D Phosphatidylcholine
(C16:0, C18:2) (*2)
0.0091 OB/D Cysteine (minor: Cystine) 0.0091 OB/D
Phosphatidylcholine
(C16:0, C18:2) (*2)
0.0091 OB/D Valine 0.0115 OB/D Phosphatidylcholine
(C16:0, C18:2) (*2)
0.0091 OB/D
5-Hydroxy-3-indoleacetic
acid (5-HIAA)
0.0116 OB/D p-Cresol sulfate (*2) 0.0133 OB/D Phenylalanine 0.0112 OB/D
p-Cresol sulfate (*2) 0.0133 OB/D Lactate 0.0140 OB/D p-Cresol sulfate (*2) 0.0133 OB/D
Lactate** 0.0140 OB/D Ribose 0.0148 OB/D Lactate 0.0140 OB/D
Phosphatidylcholine (C18:2,
C20:4) (*2)
0.0146 OB/D Glucose-1-phosphate
(minor: Glucose)
0.0167 OB/D Glucose-1-phosphate
(minor: Glucose)
0.0167 OB/D
Glucose-1-phosphate
(minor: Glucose)
0.0167 OB/D Pantothenic acid 0.0176 OB/D Pantothenic acid 0.0176 OB/D
Pantothenic acid 0.0176 OB/D Taurine 0.0181 OB/D Isoleucine 0.0209 OB/D
3-O-Methylsphingosine (minor:
Sphingolipids, erythro-
Sphingosine, threo-Sphingosine)
(*1)
0.0176 OB myo-Inositol-2-phosphate
(minor: Fructose-6-phosphate,
Glucose-6-phosphate, myo-
Inositol-1-phosphate, myo-
Inositol-4-phosphate)
0.0195 OB/D Phosphatidylcholine (C18:0,
C18:1) (*2)
0.0223 OB/D
threo-Sphingosine (minor:
Sphingolipids)
0.0232 OB Citrulline 0.0241 OB/D Ornithine (minor: Arginine,
Citrulline)
0.0237 OB/D
Threitol 0.0241 OB/D Xanthine 0.0264 OB/D Nervonic acid (C24:cis[15]1) 0.0265 OB
erythro-Sphingosine (minor:
Sphingolipids)
0.0243 OB Nervonic acid (C24:
cis[15]1)
0.0265 OB Fructose-6-phosphate
(minor: Glucose-6-
phosphate, myo-Inositol-1-
phosphate, myo-Inositol-2-
phosphate, myo-Inositol-4-
phosphate)
0.0296 OB/D
5-O-Methylsphingosine (minor:
Sphingolipids, erythro-
Sphingosine, threo-Sphingosine)
(*1)
0.0249 OB Fructose-6-phosphate
(minor: Glucose-6-
phosphate, myo-Inositol-1-
phosphate, myo-Inositol-2-
phosphate, myo-Inositol-4-
phosphate)
0.0296 OB/D Testosterone-17-sulfate
(minor:
Dehydroepiandrosterone
sulfate) (*2)
0.0299 OB
N-Acetylneuraminic acid,
lipid fraction
0.0256 OB Testosterone-17-sulfate
(minor:
Dehydroepiandrosterone
sulfate) (*2)
0.0299 OB Taurine 0.0309 OB/D
Nervonic acid (C24:
cis[15]1)
0.0265 OB gamma-Linolenic acid
(C18:cis[6,9,12]3)
0.0300 OB/D Cholic acid 0.0325 OB/D
Cholic acid 0.0279 OB Phosphatidylcholine (C18:1,
C18:2) (*2)
0.0327 OB/D Glucose 0.0376 OB/D
Metabolomics in RYGB Patients
PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7905T3 and 4
e-08 for T6, binomial test). Seventeen metabolites were
identified across all 3 lists. The top two metabolites common to
each of the 3 lists were 1,5-anhydrosorbitol and ascorbic acid.
Interestingly, 1,5-anhydrosorbitol is a biomarker currently used for
assessing glycemic control. As blood glucose levels increase above
the renal threshold for glucosuria, 1,5-anhydrosorbitol rapidly
decreases [24]. The current dataset shows that 1,5-anhydrosorbitol
levels are significantly lower in OB/D versus OB subjects
(FIGURE 4A). Following RYGB, the levels of 1,5-anhydrosorbitol
increased from T0RT3RT6, while glucose levels decreased.
Furthermore, glucose also appears in TABLE 2, which serves to
reinforce this result. The mixed-effects ANOVA model revealed a
significant group:time interaction for 1,5-anhydrosorbitol. The
second metabolite is ascorbic acid, whose abundance in serum
decreased post surgery. OB/D subjects have greater levels of
ascorbic acid versus OB subjects at all time points, despite both
groups of subjects experiencing similar decreases in ascorbic acid
levels post surgery (FIGURE 4B). No significant interaction
between group:time was identified for ascorbic acid. Deficiencies
in vitamins are a documented side-effect of gastric bypass surgery
[25,26], therefore all subjects consumed a daily multi-vitamin
containing approximately 120 mg of vitamin C post surgery. Thus
serum vitamin C differences between OB and OB/D groups in
this study are most likely not related to differences in nutritional
supplementation.
The 15 remaining metabolites that differed between OB and
OB/D subjects at all time points were asparagine, cysteine,
lysophosphatidylcholine (C18:2), phosphatidylcholine (C16:0,
C18:2), nervonic acid (C24:cis[15]1), cholic acid, pantothenic
acid, lycopene, lactate, testosterone-17-sulfate, p-Cresol sulfate,
fructose-6-phosphate, glucose-1-phosphate, glucose, and mannose.
We then determined whether the serum abundance of the
aforementioned metabolites changed significantly post surgery,
with the idea that these metabolites may then serve as candidate
markers for the improved clinical characteristics seen post surgery.
Of the 15 aforementioned metabolites, the abundance of 8
metabolites changed significantly after surgery (i.e. are found in
FIGURE 1): asparagine, lysophosphatidylcholine (C18:2), nervo-
nic (C24:1) acid, p-Cresol sulfate, lactate, lycopene, glucose, and
mannose. Lycopene, lysophosphatidylcholine, and nervonic acid
serum levels were higher in OB subjects, while asparagine, p-
Cresol sulfate, lactate, glucose and mannose were higher in OB/D
subjects.
Relationship between Metabolites and Clinical Data
We then integrated clinical and metabolite data from all three
time points in the 12 non-insulin treated subjects with the goal of
determining whether any of the aforementioned metabolites could
be used as ‘candidate’ markers that reflect the clinical adaptations
seen following RYGB. Independent Spearman correlations were
performed for each of the 8 aforementioned metabolites versus
BMI and HOMA-IR. Of the 8 metabolites examined, we
identified a significant negative correlation between nervonic acid
and HOMA-IR (p=0.001, R=20.55), i.e. HOMA-IR decreased
(FIGURE 2) as serum levels of nervonic acid increased
(FIGURE 5). This relationship was similarly observed when
considering only the 9 OB subjects independently (p=0.008,
R=20.51). Furthermore, adjusting for BMI did not affect the
significance of the correlation between nervonic acid and HOMA-
IR. No relationships were identified when correlating the delta
values for changes in BMI and HOMA-IR with these 8
metabolites (data not shown).
Discussion
Gastric bypass surgery results in significant metabolic changes
associated with weight loss, improved insulin sensitivity and
glucose homeostasis, and a reduction in co-morbidities such as
Prior to surgery (T0) 3 months post surgery (T3) 6 months post surgery (T6)
Metabolite p-value Greater in Metabolite p-value Greater in Metabolite p-value Greater in
Fructose-6-phosphate
(minor: Glucose-6-
phosphate, myo-Inositol-1-
phosphate, myo-Inositol-2-
phosphate, myo-Inositol-4-
phosphate)
0.0296 OB/D Threitol 0.0366 OB/D Citrulline 0.0439 OB/D
Testosterone-17-sulfate
(minor:
Dehydroepiandrosterone
sulfate) (*2)
0.0299 OB Glucose 0.0376 OB/D Mannose 0.0468 OB/D
Phytosphingosine 0.0302 OB Sucrose 0.0390 OB/D
Glucose 0.0376 OB/D Ornithine (minor: Arginine,
Citrulline)
0.0409 OB/D
Mannose 0.0468 OB/D Mannose 0.0468 OB/D
Arginine 0.0469 OB Phosphatidylcholine (C16:0,
C16:0) (*2)
0.0498 OB
Sphingomyelin No 02 (*2) 0.0484 OB
Metabolites were identified using a mixed-effects ANOVA: 33 metabolites at T0, 32 metabolites at T3, and 28 metabolites at T6 (p,0.05), with indication of whether
serum levels are higher in obese (OB) or obese/diabetic (OB/D) subjects. Those metabolites present in all three lists are indicated in bold font. The profiles for
metabolites whose abundance changed post surgery are found in FIGURE 1. (*1): Structure annotation is based on strong analytical evidence (combinations of
chromatography, mass spectrometry, chemical reactions, deuterium-labeling, database and literature search, as well as comparisons to similar/homologue/isomeric
reference compounds). (*2): Metabolite exhibits identical qualitative analytical characteristics (chromatography and mass spectrometry) compared to status (*1). Further
structural and analytical investigations of this metabolite - also in comparison to structurally identified or status (*1) metabolites - are still pending.
doi:10.1371/journal.pone.0007905.t002
Table 2. Cont.
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7905Figure 4. Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB. The top two metabolites distinguishing OB
and OB/D subjects were identified with the mixed-effects ANOVA allowing for group:time-interactions, where * indicates p,0.05 (versus T0). White
circles and black circles correspond to OB/D or OB subjects, respectively. Furthermore, symbols and numbers are consistently used for the same
subject in Figures 4 & 5. Mean metabolite abundance6SEM is indicated in red. A) A significant increase in 1,5-anhydrosorbitol (1,5-AG) occurred at T6
vs. T0 in OB/D subjects, while a non-significant increase was seen in OB subjects (group:time interaction was allowed for by the linear model). B) For
ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases
from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D
subgroups (p,0.01, see TABLE 2).
doi:10.1371/journal.pone.0007905.g004
Figure 5. Increases in nervonic acid following RYGB. A significant increase in serum abundance of nervonic acid occurred following RYGB in
both OB and OB/D subjects, as assessed using a mixed-effects ANOVA with group:time interaction (** p,0.01 versus T0). Overall, nervonic acid levels
were significantly different at each time point between OB and OB/D subgroups (p,0.01, see TABLE 2). No group:time interaction was identified.
Mean metabolite abundance6SEM is indicated in red.
doi:10.1371/journal.pone.0007905.g005
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approximately 10,000 subjects who had undergone gastric bypass
surgery revealed that mortality related to diabetes decreased by
over 90%, leading to this medical procedure being proposed as a
means to treat diabetes, even in subjects who are obese rather than
morbidly obese [3]. As such, there is significant interest in
unraveling the molecular adaptations underlying the improved
insulin sensitivity seen post RYGB. We performed a global
metabolite profiling analysis in morbidly obese female subjects
before and after RYGB in order to generate new knowledge
regarding the physiological and metabolic changes arising with this
procedure.
All 14 patients experienced an improvement in the clinical
parameters measured. Decreases in BMI, body weight, fat mass,
fat free mass, triglycerides, insulin resistance (HOMA-IR), and
leptin were observed following RYGB. Subjects also experienced a
decrease in resting energy expenditure. Furthermore, while total
caloric intake decreased dramatically post surgery, the relative
proportion of protein, lipid, and carbohydrate consumed in the
diet remained stable. The OB/D subjects had additional
physiological improvements post surgery related to their diabetes
status. OB/D subjects experienced a drop in HbA1C levels at 3
months post RYGB. Three of the 5 OB/D subjects demonstrated
a resolution of diabetes, as suggested by the normalization of
glucose levels and the fact they no longer needed anti-diabetic and
dyslipidemia treatments after 3 months. The remaining 2 OB/D
subjects demonstrated improvements in their diabetic status, but
insulin therapy was still required. Interestingly, these two subjects
both had diabetes for 11 years prior to surgery and higher pre-
surgery HbA1c levels in contrast with the other three subjects, who
had diabetes for 5 years prior to surgery and lower pre-surgery
HbA1c levels. This suggests the RYGB surgery may be more
efficacious for resolving diabetes if performed soon after diagnosis
in subjects with low HbA1C levels.
In the present study we have identified 83 serum metabolites
whose abundance changed significantly following RYGB; where
the majority of these metabolites corresponded to lipids and amino
acids. The use of a stringent Bonferroni adjustment to correct for
multiple testing highlighted the large number of metabolites that
decreased immediately post surgery and then did not change
between T3 and T6 (FIGURE 1). To the best of our knowledge,
previous lipid analyses before and after gastric bypass surgery have
only focused on lipoproteins and lipid classes, but not individual
lipid species. The improvements in dyslipidemia associated with
gastric bypass were previously demonstrated by increases in HDL-
cholesterol and reductions in total cholesterol, LDL-cholesterol,
and triglycerides [6,27]. More recently, Schwab et al. performed an
analysis of the lipid-fraction of the serum metabolome in subjects
before and after diet-induced weight loss. Although diet restriction
is a considerably less dramatic weight loss situation than RYGB,
the authors found that diet-induced weight loss led to decreases in
triglycerides and phospholipids, but no changes to lysophospha-
tidylcholine (LPC) and sphingolipid species [13]. The lack of
changes in LPC and sphingolipids was surprising when consider-
ing previous animal studies have shown that LPC species and
sphingolipids are increased with obesity and in situations marked
by impaired insulin sensitivity [14,15,28]; however, it is plausible
that less drastic weight-loss paradigms such as exercise and diet
restriction do not affect insulin sensitivity sufficiently to detect
changes in LPC and sphingolipids.
While many lipid species were found to increase in subjects post
RYGB, several lipids were of particular interest, namely nervonic
acid and various sphingosine species (3-O-methylsphingosine,
threo-sphingosine, erythro-sphingosine, and 5-O-methylsphingo-
sine). In light of recent evidence regarding the role of
intramyocellular lipids (IMCL) and insulin resistance, it is
interesting to speculate that plasma increases in the aforemen-
tioned lipids reflect their mobilization from non-adipose tissues
such as the muscle. Elevated IMCL deposition has been observed
in obese individuals, obese subjects with type 2 diabetes and
insulin resistant subjects [29,30]. One year after elective gastric
bypass surgery, Gray et al. found a ,30% decrease in IMCL and
hypothesized that decreases in muscle lipid content may contribute
to improved insulin action [29]. More specifically, intramyocel-
lular sphingolipids may cause insulin resistance by disrupting
insulin signaling pathways in the muscle [31]. Previous reports
have revealed that the level of muscle ceramide enriched with
nervonic acid is negatively correlated with insulin sensitivity, but
the authors did not examine plasma lipid levels. Recently, Haus
and colleagues have found that serum ceramide enriched with
nervonic acid is inversely correlated with insulin sensitivity [30];
however, the authors did not determine free levels of circulating
nervonic acid. In light of our findings demonstrating increases in
total serum nervonic acid post RYGB and its negative correlation
with insulin resistance, it would be interesting to simultaneously
generate metabolomic datasets in both the muscle and plasma
before and after RYGB in order to determine whether the release
of IMCL is responsible for the increased serum lipid levels we
observed. Additionally, it will be interesting to determine whether
decreases in IMCL correlate with the loss of fat free mass, also
observed post gastric bypass surgery [32,33]. This would provide
further insight into the flux of lipids and reveal whether IMCL are
mobilized into serum following RYGB.
Our work also revealed that branched chain amino acids (BCAA)
serum levels decreased followingRYGB. The decrease in valinewas
paralleled by an increase in serum b-aminoisobutyric acid, a
product of valine catabolism. Our results are in line with a previous
report indicating that plasma BCAA decrease by approximately
35% following gastric bypass surgery [34]. The subjects in this
independent studyshowed a significant decrease inbody weight and
plasma glucose levels, but no improvement in insulin sensitivity;
however, this may be a result of the increased inter-individual
variability associated with the use of a mixed-sex cohort. The
authors also demonstrated an increase in both subcutaneous and
visceral adipose tissue mitochondrial BCAA aminotransferase
(BCATm) protein levels, a key enzyme involved in BCAA
catabolism. As such, the authors proposed that lower plasma
BCAA levels post gastric bypass surgery reflect an increase in
adipose tissue BCAA catabolism. The same authors demonstrated
elevated plasma BCAA levels in a BCATm 2/2 mouse model
[35]; however, differences between mice and humans can be noted
in these studies. Specifically, elevated BCAA levels were associated
with improved glucose and insulin tolerance in BCATm2/2 mice,
while decreases in BCAA levels are associated with improved
glucose and insulin tolerance in humans following RYGB. The
results in humans were recently reinforced by two independent
studies and demonstrated that BCAA plasma levels are higher in
obese subjects versus their non-obese subjects [16,36]. Furthermore,
the expression of genes associated with the BCAA catabolic
pathway were significantly decreased in subcutaneous adipose
tissue of obese twins, and this was additionally associated with
insulin resistance [36]. This suggests that high levels of circulating
BCAA are associated with an insulin resistant state, as recently
discussed by Newgard et al [16]. Thus it can be hypothesized that
increases in BCAA catabolism result in lower circulating BCAA
levels which are associated with improved insulin sensitivity in
humans. Our results agree with this hypothesis, as all three BCAA
decrease post RYGB where insulin sensitivity improves.
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following RYGB, we have chosen to briefly discuss some
metabolites that were significantly different at an unadjusted
0.05 p-level to highlight potentially promising metabolites for
further study. These metabolites provide intriguing and novel
information illustrating the many physiological adaptations arising
post RYGB; although their relationship with RYGB, morbid
obesity, and diabetes has not been extensively studied. For
example, RYGB was previously shown to improve hypothyroidism
[37]. We have identified a significant increase in thyroxine (T4),
the major form of thyroid hormone found in blood, post surgery
that may underlie the improvement in thyroid function and
signaling seen in subjects after RYGB. The abundance of protein-
bound uremic retention solutes (p-cresol sulfate, indole-3-acetic
acid, 3-indoxylsulfuric acid, and 3-hydroxyindole) was increased
post RYGB and, several of the precursor metabolites were
decreased after bypass surgery, such as tyrosine, phenylalanine,
and tryptophan [38]. Serum increases in these metabolites are
typically associated with renal failure; however, the increased
abundance of these metabolites may be a consequence of
modifications to the gut environment [39]. Indeed, p-cresol and
indole are metabolites generated by the intestinal microbiota,
suggesting that RYGB may lead to alterations in the gut microbial
composition. The serum abundance for a number of phytochem-
icals was also altered following gastric bypass surgery. More
specifically, beta-sitosterol and campesterol were decreased, and
lycopene and beta-carotene were increased. Phytochemicals are
bioactive, non-nutritional molecules derived from plant sources
and whose consumption is generally associated with a reduced risk
for various diseases, such as cardiovascular disease and cancer
[40,41]. Although controversial, plasma increases in plant sterols
(e.g. campesterol and beta-sitosterol) have been associated with an
increased risk for coronary heart disease [42]; thus our data may
suggest RYGB reduces the abundance of these risk factors.
Phytochemicals can be absorbed to a certain extent all along the
gastrointestinal tract; however, they are predominantly absorbed
in the duodenum and jejunum [40]. Therefore it is possible that
the changes observed in serum phytochemical abundance is a
consequence of the physical restructuring of the gastrointestinal
tract during RYGB surgery that involves bypassing much of the
proximal small intestine. Although the mechanisms underlying
changes in the serum abundance of the aforementioned metab-
olites is unclear at present, our study has yielded novel and
intriguing avenues of research that will ultimately provide a deeper
understanding of the numerous physiological and metabolic
consequences of gastric bypass surgery.
We further studied whether changes in metabolite abundance
were associated with diabetes by separating our cohort into obese
and obese/diabetic subjects. We felt this analysis was justified and
valid for several reasons. Firstly, subgroup analysis between OB
and OB/D subjects was only performed when statistical
significance was achieved according to Akaike information
criterion. Secondly, metabolite profiling revealed that glucose
was greater in OB/D subjects compared to OB subjects at all three
time points (p,0.05). Thirdly, the metabolite that differed the
most between OB and OB/D subjects was 1,5-anhydrosorbitol
(p,0.001), a biomarker currently used for assessing glycemic
control [24]. This metabolite was more abundant in OB/D serum.
Furthermore, blood levels of 1,5-anhydrosorbitol are inversely
related to glucose, which our data also confirms. Finally, OB/D
subjects showed a marked improvement in their diabetic status.
Three of the five OB/D subjects demonstrated a resolution of
diabetes and no longer required treatments related to diabetes or
dyslipidemia. Thus, any differences between OB and OB/D that
may be related to pre-surgery diabetes treatment would have less
importance post surgery. Nevertheless, to avoid this potential
confounder, we have only focused on metabolites that are
systematically identified at all three time points to differentiate
OB and OB/D subjects. Eight metabolites were found to both
differentiate OB from OB/D subjects consistently at all time
points and change over time (T0 vs. other two time points T3, T6):
lycopene, asparagine, lysophosphatidylcholine (C18:2), p-Cresol
sulfate, lactate, nervonic acid (C24:cis[15]1), glucose, and
mannose. We integrated data for the 8 aforementioned metabo-
lites with the clinical data available for our subjects regarding BMI
and HOMA-IR. Nervonic acid was found to be negatively
correlated with HOMA-IR, which is of particular interest
considering that this fatty acid has previously been positioned as
having preventive effects on obesity-related metabolic parameters
[43]. While little else is known regarding its functional role in
obesity, it will be interesting to determine whether nervonic acid
induces or is simply a consequence of the metabolic improvements
seen post RYGB.
In summary, applying global metabolite profiling to the study of
subjects before and after RYGB has provided considerable new
information regarding the numerous alterations to serum metab-
olite levels arising with this surgical procedure. While we have
identified metabolites not previously associated with the physio-
logical and metabolic alterations arising with gastric bypass
surgery, it is imperative that the next step taken in unraveling
the physiological improvements following RYGB uses a systems
biology approach to study metabolite fluxes between serum,
muscle, liver, and adipose tissue. The additional knowledge
regarding the communication between tissues and body fluids
will permit a better understanding of whether metabolite changes
are responsible for, or an indirect effect of, clinical improvements.
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